Direct Ex Vivo Evaluation of Long‐Lived Protective Antiviral Memory B Cell Responses against Hepatitis B Virus

Ward, Scott M.; Phalora, Prabhjeet; Bradshaw, Daniel; Leyendeckers, Heike; Klenerman, Paul

doi:10.1086/591094

Cited by 31 publications

(31 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that a sustained B lymphocytemediated immune response, namely a memory B lymphocyte response, against HBV provides protection against further HBV infection. 22 The present study suggested that loss of memory B lymphocytes in chronic HBV infection may play a role in the persistence of HBV infection and progression to HCC. Alternatively, the abnormalities found in the B lymphocyte subsets might reflect the direct effects of HCC.…”

Section: Discussionmentioning

confidence: 53%

“…The interaction between HBV and B lymphocytes might be explained by defects in humoral immunity in individuals who develop HCC. 22 Chi et al 23 demonstrated that effective neutralization of HBV might be achieved by low-affinity binding of antibody to nonepitope regions of preS1. Naïve B lymphocytes can be bound to and activated by HBV capsid (core antigen), which stimulates them to become efficient antigenpresenting cells that can prime T lymphocytes and induce an effective immune response.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Decreased CD27 on B Lymphocytes in Patients with Primary Hepatocellular Carcinoma

Wang

et al. 2012

J Int Med Res

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 53%

Section: Discussionmentioning

confidence: 99%

Decreased CD27 on B Lymphocytes in Patients with Primary Hepatocellular Carcinoma

Wang

et al. 2012

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…Memory lymphocyte-mediated protection against infection may persist despite low serum antibody titers, as has been shown for the hepatitis B vaccine. 14 In the current study, monovalent HPV-16 vaccine recipients who were cLIA seronegative at the pre-dose 1 visit also mounted a robust immune response following administration of the quadrivalent HPV-6/11/16/18 vaccine. This suggests that, although these women maintained a low immune response over time, they likely did have immune memory lymphocytes capable of providing a robust immune response.…”

Section: Discussionmentioning

confidence: 61%

Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine

Rowhani-Rahbar

Alvarez

Bryan

et al. 2012

Journal of Clinical Virology

View full text Add to dashboard Cite

Background The duration of protection conferred by prophylactic human papillomavirus (HPV) L1 virus-like particle vaccines is a critical determinant of their public health impact. A feature of vaccines that confer long-term immunity is their ability to induce immune memory. Objectives We evaluated antibody responses against HPV types 6, 11, 16 and 18 following administration of the quadrivalent HPV-6/11/16/18 vaccine to women who had previously received a monovalent HPV-16 vaccine. Study design As part of an extended follow-up study conducted between 2006 and 2009 in Seattle, Washington, we administered the quadrivalent HPV-6/11/16/18 vaccine to 52 women (19 vaccine and 33 placebo recipients) who had participated in a monovalent HPV-16 vaccine trial 8.5 years earlier. Serum samples were tested for anti-HPV antibodies using competitive Luminex immunoassay. Results Following administration of the first dose of the quadrivalent HPV-6/11/16/18 vaccine, the anti-HPV-16 geometric mean titer among monovalent HPV-16 vaccine recipients (GMT = 5024.0 milli-Merck units per milliliter [mMU/mL]; 95% confidence interval [CI]: 2710.1, 9313.6 mMU/mL) substantially exceeded that among the placebo recipients (GMT = 136.1; 95% CI: 78.5, 235.8 mMU/mL; p < 0.01) and their own highest anti-HPV-16 response observed during the original trial (GMT at month 7 of the original trial = 1552.7 mMU/mL; 95% CI: 1072.6, 2247.7 mMU/mL; p < 0.01). Conclusions The findings suggest that the administration of the three-dose regimen of the monovalent HPV-16 vaccine had produced memory lymphocytes, characterized by a heightened immune response following administration of the quadrivalent HPV-6/11/16/18 vaccine that effectively served as an antigen challenge.

show abstract

“…In the present study, the level of serum anti-HBsAb was < 10 mIU/mL in 4 of the 13 children who were negative for HBsAg after prophylactic treatment. Although it is controversial whether booster vaccination is required to maintain adequate levels of anti-HBs antibodies [28-30], all of the 4 children were negative for serum HBV DNA. All of these children had levels of anti-HBs antibodies >10 mIU/mL at 1 year after birth.…”

Section: Discussionmentioning

confidence: 99%

Cellular immunity in children with successful immunoprophylactic treatment for mother-to-child transmission of hepatitis B virus

et al. 2010

Self Cite

View full text Add to dashboard Cite

BackgroundThe administration of hepatitis B immunoglobulin followed by hepatitis B vaccine can result in a protective efficacy of almost 90% in mother-to-child transmission of hepatitis B virus (HBV). However, little is known about immunity against HBV infection in children after immunoprophylactic treatment. We tried to assess the association between T-cell responses and viremia in children after successful prophylactic treatment.MethodsThirteen children and their 8 HBV carrier mothers (8 families), who were positive for human leukocyte antigen (HLA)-A24, were enrolled in this study. All of the 13 children received immunoprophylactic treatment and became negative for hepatitis B surface antigen (HBsAg) after birth. HBV-specific cytotoxic T lymphocyte (CTL) responses were evaluated using IFNγ - enzyme-linked immunosorbent spot (ELISPOT) and major histocompatibility complex class I peptide pentamer assays. Serum HBV DNA was measured by real-time PCR.ResultsSignificant HBV-specific T-cell responses were detected in 2 (15%) of the 13 children by ELISPOT. However, the frequency of HLA-A24-HBV-specific CTLs was very low in both HBV carrier mothers and children using pentamers. Of the 13 children, 4 (31%) were positive for serum HBV DNA. However, the levels of serum HBV DNA were 100 copies/ml or less. One of the 2 children in whom significant HBV-specific CTL responses were detectable was positive for serum HBV DNA.ConclusionsHBV core and polymerase-specific T-cell responses were detected and a low-dose viremia was observed in children after successful immunoprophylaxis treatment. Although the presence of viremia was not related to HBV-specific T-cell responses, CTLs might play a role in the control of HBV infection in children born to HBsAg-positive mothers after immunoprophylactic treatment.

show abstract

Direct Ex Vivo Evaluation of Long‐Lived Protective Antiviral Memory B Cell Responses against Hepatitis B Virus

Abstract: Our results indicate sustained B cell-mediated protection against HBV despite waning antibody titers, which is consistent with clinical observations.

Cited by 31 publications

References 14 publications

Decreased CD27 on B Lymphocytes in Patients with Primary Hepatocellular Carcinoma

Decreased CD27 on B Lymphocytes in Patients with Primary Hepatocellular Carcinoma

Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine

Cellular immunity in children with successful immunoprophylactic treatment for mother-to-child transmission of hepatitis B virus

Contact Info

Product

Resources

About